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Introduction: The incidence of invasive pulmonary aspergillosis (IPA) in intensive care unit (ICU) patients is
increasing, and early diagnosis of the disease and treatment with antifungal drugs is critical for patient survival.
Serum biomarker tests for IPA typically give false-negative results in non-neutropenic patients, and galactomannan
(GM) detection, the preferred diagnostic test for IPA using bronchoalveolar lavage (BAL), is often not readily
available. Novel approaches to IPA detection in ICU patients are needed. In this multicenter study, we evaluated
the performance of an Aspergillus lateral-flow device (LFD) test for BAL IPA detection in critically ill patients.
Methods: A total of 149 BAL samples from 133 ICU patients were included in this semiprospective study.
Participating centers were the medical university hospitals of Graz, Vienna and Innsbruck in Austria and the
University Hospital of Mannheim, Germany. Fungal infections were classified according to modified European
Organization for Research and Treatment of Cancer/Mycoses Study Group criteria.
Results: Two patients (four BALs) had proven IPA, fourteen patients (sixteen BALs) had probable IPA, twenty
patients (twenty-one BALs) had possible IPA and ninety-seven patients (one hundred eight BALs) did not fulfill IPA
criteria. Sensitivity, specificity, negative predictive value, positive predictive value and diagnostic odds ratios for
diagnosing proven and probable IPA using LFD tests of BAL were 80%, 81%, 96%, 44% and 17.6, respectively. Fungal
BAL culture exhibited a sensitivity of 50% and a specificity of 85%.
Conclusion: LFD tests of BAL showed promising results for IPA diagnosis in ICU patients. Furthermore, the LFD test
can be performed easily and provides rapid results. Therefore, it may be a reliable alternative for IPA diagnosis in
ICU patients if GM results are not rapidly available.
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Invasive pulmonary aspergillosis (IPA) caused by the
ubiquitous environmental mold Aspergillus is a leading
cause of morbidity and mortality in immunocomprom-
ised patients, including those in intensive care units
(ICUs) [1]. Well-known risk factors for IPA (for ex-
ample, prolonged neutropenia, stem cell or solid organ
transplant (SOT)) are present in a significant number of
patients who develop IPA in the ICU [2]. However, IPA
has also been reported in ICU patients lacking classical
risk factors [3-5], including those with chronic obstructive
pulmonary disease (COPD), systemic use of corticosteroids,
advanced liver disease, severe sepsis, septic shock and acute
renal failure [5-8]. Although researchers in a previous
study reported an incidence of about 5.8% [9], the true
incidence of IPA in the ICU remains unknown.
Timely use of antifungal drugs significantly decreases
IPA-related mortality in high-risk patients [10]; thus,
early diagnosis is a crucial cornerstone of successful IPA
management. Early diagnosis remains a challenge, how-
ever, as clinical signs and symptoms and diagnostic im-
aging are often non-specific. Also, conventional culture
methods lack sensitivity, and tissue biopsy is invasive
and rarely possible in critically ill patients. IPA diagnosis
is particularly challenging in ICU patients without un-
derlying hematologic malignancies. First, chest X-rays
and computed tomographic images are often difficult to
interpret, as many of them show pulmonary infiltrates,
atelectasis or signs of preexisting lung tissue damage
[11]. Second, diagnostic Aspergillus galactomannan (GM)
determination in serum seems less reliable in non-neutro-
penic patients than in patients with neutropenia, as the
angioinvasive growth of Aspergillus in non-neutropenic pa-
tients is typically confined by the local immune response in
lung tissues. Therefore, the level of circulating GM in the
bloodstream may be too low to be detected [12,13].
Detection of GM in bronchoalveolar lavage (BAL) fluid
and conventional microbiological culture of BAL fluid
samples are the current preferred tests for IPA diagnosis
in ICU patients [3,14,15]. GM is a polysaccharide cell
wall component of Aspergillus species that is released
during active growth. Using a commercially available en-
zyme-linked immunosorbent assay, GM can be detected
in BAL fluid, blood, urine and cerebrospinal fluid [16-18].
However, GM detection has some limitations. Factors
such as comedications (for example, β-lactam antibiotics),
underlying diseases, host factors (for example, renal failure
and/or renal replacement therapy), radiologic findings and
clinical signs have to be considered for the correct inter-
pretation of GM levels [19-22]. One of the crucial limi-
tations of the GM test is the need for appropriately
equipped laboratories where the test can be performed by
trained staff, leading to variable turnaround times, which
can be up to several days [14].Many of these limitations are overcome by the Aspergil-
lus-specific lateral-flow device (LFD) test, a novel and
rapid single-sample test for IPA diagnosis. Because of its
simplicity, the LFD test can be performed in rudimen-
tary facilities with minimal staff training. Patient BAL
fluid samples do not need pretreatment, which means
that test results can be available within 10 to 15 minutes
of sample receipt. This point-of-care test uses a mono-
clonal antibody (mAb JF5) to detect an extracellular
mannoprotein antigen that is secreted exclusively dur-
ing active growth of Aspergillus species [23,24]. LFD test
results are read by the naked eye, and they have previ-
ously been shown to be reproducible between different
studies and different laboratories [25]. Previous studies
have shown the remarkable diagnostic potential of the
LFD test in diagnosing IPA using BAL fluid samples
[26-30], but data on the performance of the LFD test in
ICU patients are limited, with only two previous single-
center studies of subsets of ICU patients [29,30]. In this
multicenter study, we evaluated the LFD test using BAL
fluid specimens for early diagnosis of IPA in ICU patients.
Materials and methods
This multicenter cohort study was performed at the
three Austrian medical university hospitals (in Graz,
Innsbruck and Vienna) and the University Hospital of
Mannheim, Germany. The study comprised 149 previ-
ously unpublished BAL fluid samples obtained from 133
ICU patients with clinical suspicion of IPA who were
tested routinely for the presence of Aspergillus species be-
tween January 2010 and June 2014. The decision whether
to obtain BAL samples and send them for mycological
workup was completely up to the treating physician’s dis-
cretion. Patients with SOT were excluded from the ana-
lysis. Samples at the Medical University Hospital of Graz,
Austria (n = 70), the Medical University Hospital of
Vienna, Austria (n = 18) and the University Hospital of
Mannheim, Germany (n = 10), were included prospectively
between February 2012 and June 2014. In Vienna, samples
were included only if they had a positive Aspergillus cul-
ture result. Patients at the Medical University Hospital of
Innsbruck were included, in part, prospectively (n = 31;
January 2013 to June 2013). In Innsbruck, another 20 sam-
ples were tested retrospectively for patients who had been
included in the Innsbruck fungal infection biobank sample
collection between 2010 and 2012 (samples frozen at−70°C).
Data of this manuscript were presented previously in poster
presentations at three conferences: the Sixth Advances
Against AspergillosisMeeting 2014 [31], the 2014MYKmeet-
ing [32], and IDWeek 2014 [33]. Other than that no data of
patients included in this study have been published previously.
Patients were classified as having proven, probable,
possible or no IPA in accordance with slightly revised
criteria of the European Organization for Research and
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MSG) [34], with the inclusion of ICU stay above 4 days
as a host factor [15,16]. Modifications were necessary be-
cause host factors in these guidelines were originally de-
fined for patients with hematologic malignancies, and a
significant proportion of ICU patients with IPA do not ful-
fill these host factors [35]. This was shown by Blot and
colleagues, with EORTC/MSG host factors being absent
in approximately 30% of proven IPA cases [35]. In previ-
ous studies, the median (interquartile range (IQR)) time
from ICU admission to development of IPA was between
2 days (IQR, 1 to 9) and 4 days (IQR, 1 to 8) [35,36].
Therefore, we decided to introduce ICU stay above 4 days
as an additional host factor in our modified EORTC/MSG
criteria. In addition, we evaluated test performance when
classifying IPA according to the predefined EORTC/MSG
criteria (without ICU stay as a host factor) [34] and a pre-
viously published clinical algorithm [35], instead of our
modified EORTC/MSG criteria.
Depending on where the patient was included in the
study, LFD testing was performed at the Microbiology
Laboratory, Department of Internal Medicine, Medical
University of Graz; the Institute of Hygiene and Micro-
biology, Innsbruck Medical University; the Division of
Clinical Microbiology, Medical University of Vienna,
Austria; or the scientific laboratory, Department of Hema-
tology and Oncology, Mannheim University Hospital,
Germany. For LFD testing, 100 μl of untreated BAL fluid
samples were applied to the LFD. The results were read
by the naked eye and interpreted after a 15-minute incu-
bation at room temperature, as recommended previously
[23]. Bound antigen–antibody–gold complexes were re-
corded as a red line with intensity proportional to the
antigen concentration. Test line intensity ranged from
strong positive (+++) to weak positive (+) or negative
(−) [25] and depended on the antigen contents of BAL
fluid samples. Regardless of the intensity of the test
lines, all positive results indicated germination of spores
and existence of hyphae in the lungs and were therefore
interpreted as positive. Test results were compared with
routinely performed BAL GM tests, direct microscopic
and culture results.
Statistical analysis was performed using SPSS version
22 software (IBM, Armonk, NY, USA). The diagnostic
performance of the LFD test for probable or proven IPA
versus no IPA (putative or proven IPA when using the
alternative clinical algorithm) were evaluated, and negative
predictive value (NPV), positive predictive value (PPV),
sensitivity and specificity were calculated. Additionally,
diagnostic odds ratios (DORs) with 95% confidence in-
tervals (95% CIs) were determined.
This study was conducted in accordance with the
Declaration of Helsinki (1996), Good Clinical Practice
and applicable local regulatory requirements and law. Thestudy protocol was approved by the local ethics committee
at the Medical University Graz, Austria (EC number 25-
221 ex 12/13), as well as by the ethics committees of the
Medical University of Vienna (EC number 1656/2013)
and the Medical University of Innsbruck (EC number UN
4926), and the trial is registered at ClinicalTrials.gov
(identifier NCT02058316). As clinical data of patients
treated at the Mannheim University Hospital were ana-
lyzed retrospectively with a scientific intent and data were
concurrently obtained pseudonymized, approval by the
local ethics committee (Faculty of Medicine in Mannheim
Ethics Committee) was not required according to the
German ethics committee regulations. All data presented
have been deidentified and are therefore not attributable
to individual patients. The ethics committees waived
written informed consent of participating patients. The
performance evaluation of a medical product was also
reported to the Austrian Agency for Health and Food
Safety (protocol number INS-621000-0478).
Results
A total of 149 BAL fluid samples from 133 patients were
included in the final analysis. All patients were treated in
an ICU setting at the time bronchoscopy was performed.
The median age of the study population was 60 years
(range, 19 to 85), and 65.4% (n = 87) were men and 34.6%
(n = 46) were women. The demographic characteristics and
underlying diseases of the study population are shown in
Table 1. Known risk factors for IPA were present in the
majority of the study population, and these included
COPD (32 (21.5%) of 149;), acute leukemia (18 (12%) of
149), neutropenia (18 (12%) of 149), chronic systemic cor-
ticosteroid use (11 (7%) of 149), bone marrow transplant-
ation (9 (6%) of 149), bronchial carcinoma (8 (5%) of 149),
influenza A viral pneumonia (7 (5%) of 149) and liver cir-
rhosis and/or alcoholic hepatitis (6 (4%) of 149).
Our classification of IPA in accordance with the mo-
dified EORTC/MSG diagnostic criteria is depicted in
Table 1. Overall, 12% (16 of 133) of patients (20 (13.4%)
of 149 BALs) had probable or proven IPA. Both patients
with proven IPA died, one of whom had acute myeloid
leukemia and had undergone recent allogeneic stem cell
transplant and the other of whom had acute-on-chronic
liver failure and a prolonged ICU stay. As the primary
underlying disease among the patients with probable
IPA, four had underlying COPD (one with inherited im-
munodeficiency and three with systemic corticosteroid
treatment), four septic pneumonia (including two with
influenza A viral pneumonia), three had underlying
hematologic malignancies, two had liver cirrhosis and/or
alcoholic hepatitis and one had trauma. The majority of
patients with probable IPA (9 of 14 patients, 11 of 16
BALs) did fulfill EORTC/MSG host factors, whereas 5 of
14 patients (5 of 16 BALs) with probable IPA fulfilled only
Table 1 Demographic data and underlying diseases of intensive care unit patients with bronchoalveolar lavage lateral-
flow-device test resultsa
Present study population Graz Innsbruck Vienna Mannheim
Number of BALs/patients 149/133 70/61 51/49 18/13 10/10
Sex
Male 87 (65.4%) 45 (51.7%) 28 (32.2%) 6 (6.9%) 8 (9.2%)
Female 46 (34.6%) 16 (34.8%) 21 (45.7%) 7 (15.2%) 2 (4.3%)
Median age (range) 60 (19 to 85) 66 (19 to 83) 58 (26 to 85) 59.5 (41 to 74) 55.5 (40 to 75)
Type of ICU admission (BALs)
Medical 121/149 (81.2%) 60/70 (85.7%) 35/51 (68.6%) 16/18 (88.9%) 10/10 (100%)
Neurologic 6/149 (4%) 5/70 (2.9%) 1/51 (2%) – –
Elective surgery 2/149 (1.3%) – 1/51 (2%) 1/18 (5.6%) –
Emergency surgery 8/149 (5.4%) 4/70 (5.7%) 4/51 (7.8%) – –
Trauma 12/149 (8.1%) 1/70 (1.4%) 10/51 (19.6%) 1/18 (5.6%) –
Primary underlying disease (BALs)
Pulmonary disease 44/149 (29.5%) 21/70 (30%) 14/51 (27.5%) 6/18 (33.3%) 3/10 (30%)
Heart disease 25/149 (16.8%) 17/70 (24.3%) 4/51 (7.8%) 4/18 (22.2%) –
Hematologic malignancies 19/149 (12.8%) 8/70 (11.4%) 3/51 (5.9%) 2/18 (11.1%) 6/10 (60%)
Trauma 12/149 (8.1) 1/70 (1.4%) 10/51 (19.6%) 1/18 (5.6%) –
Neurologic disease 14/149 (9.4%) 11/70 (15.7%) 3/51 (5.9%) – –
Gastrointestinal disease 13/149 (8.7%) 3/70 (4.3%) 7/51 (13.7%) 3/18 (16.7%) –
Metabolic disease 4/149 (2.7%) 1/70 (1.4%) 3/51 (5.9%) – –
Other malignancies 5/149 (3.4%) 3/70 (4.3%) 2/51 (3.9%) – –
Rheumatologic disease 4/149 (2.7%) 3/70 (4.3%) – – 1/10 (10%)
Others 9/149 (6%) 2/70 (2.9%) 5/51 (9.8%) 2/18 (11.1%) –
IPA classification
Proven IPA (BALs/patients) 4/2 – – 3/1 1/1
Probable IPA (BALs/patients) 16/14 6/6 8/7 2/1 –
Possible IPA (BALs/patients) 21/20 6/5 6/6 – 9/9
No IPA (BALs/patients) 108/97 58/50 37/36 13/11 –
aBAL, Bronchoalveolar lavage; COPD, Chronic obstructive pulmonary disease; IPA, Invasive pulmonary aspergillosis.
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days (all of them had ICU stays of 10 days or longer).
GM testing was performed in ten BAL fluid samples of
patients with probable IPA, and the results were positive
in nine of those (two of those BALs also yielded a positive
culture for Aspergillus spp.). Cultures for Aspergillus were
also positive in the remaining 7 of the 16 BAL fluid sam-
ples of patients with probable IPA; GM evaluation was not
performed in 6 of these 7 samples.
The sensitivity and specificity of the BAL LFD test for
diagnosing probable or proven IPA (versus no IPA) in
our cohort were 80% and 81%, respectively, when we used
the modified EORTC/MSG classification (and 87% and
81%, respectively, when we used predefined EORTC/MSG
criteria). The LFD test performance for probable or pro-
ven IPA versus no IPA (and putative or proven IPA versus
no IPA) is depicted in Table 2. The sensitivity of the BALLFD test in samples with a positive GM test was 89%
(eight of nine samples had positive LFD results). In sam-
ples of probable cases (according to modified EORTC/
MSG criteria) with a positive culture but without GM
evaluation, the sensitivity was 75% (six of eight samples
had a positive LFD result).
Positive LFD test results were found in 20 (19%) of
108 BAL fluid samples from 18 patients who did not
fulfill modified EORTC/MSG IPA criteria. In 6 (30%) of
these 20 BAL fluid samples, the patients (n = 6) had my-
cological evidence of mold infection. Conventional BAL
cultures grew Aspergillus species in all six cases, and one
patient had a positive BAL culture, and a highly positive
BAL GM level (optical density index (ODI) = 5.77) and a
positive serum GM level; however, this patient did not ful-
fill radiological and clinical criteria for IPA. Most false-
positive LFD tests (n = 14) revealed only a weak positive
Table 2 Aspergillus-specific lateral-flow device test performance for diagnosing probable or proven versus no invasive
pulmonary aspergillosisa
Sensitivity Specificity PPV NPV DOR (95% CI)
Modified EORTC/MSG criteria [34]b
Overall study population 80% (16/20) 81% (88/108) 44% (16/36) 96% (88/92) 17.6 (5.3 to 58.3)
Graz 83% (5/6) 79% (46/58) 29% (5/17) 98% (46/47) 19.2 (2.0 to 179.9)
Innsbruck 75% (6/8) 95% (35/37) 75% (6/8) 95% (35/37) 52.5 (6.2 to 447.6)
Vienna 80% (4/5) 54% (7/13) 40% (4/10) 88% (7/8) 4.7 (0.4 to 54)
Mannheimc 100% (1/1) 78% (7/9) 33% (1/3) 100% (7/7) 9 (0.3 to 200)
Original revised EORTC/MSG criteria [34]
Overall study population 87% (13/15) 81% (101/124) 36% (13/36) 98% (101/103) 28.5 (6 to 135)
Clinical algorithm according to Blot et al. [35]
Overall study population 83% (10/12) 79% (108/137) 26% (10/39) 98% (108/110) 18.6 (3.9 to 89.7)
aCI, Confidence interval; DOR, Diagnostic odds ratio; EORTC/MSG, European Organization for Research and Treatment of Cancer/Mycoses Study Group; NPV,
Negative predictive value; PPV, Positive predictive value. bIncluding intensive care unit stay longer than 4 days as a newly introduced host factor and bronchoalveolar
lavage fluid galactomannan >0.5. cResults from Mannheim represent Aspergillus-specific lateral-flow device test performance for probable or proven versus possible or
no invasive pulmonary aspergillosis (IPA), owing to the fact that only proven and possible cases were reported by this center. Classification was carried out according to
EORTC/MSG criteria with and without modifications (possible IPA cases were excluded), and proven or putative IPA versus no IPA was classified according to the clinical
algorithm published by Blot and colleagues [35].
Table 3 Comparison of Aspergillus-specific lateral-flow
device test and conventional bronchoalveolar lavage
culture performance for diagnosing probable or proven
versus no invasive pulmonary aspergillosisa
Probable or proven IPA
versus no IPA
LFD Conventional
BAL culture
Sensitivity 80% (16/20) 50% (10/20)
Specificity 81% (88/108) 85% (88/103)
PPV 44% (16/36) 40% (10/25)
NPV 96% (88/92) 90% (88/98)
DOR (95% CI) 17.6 (5.3 to 58.3) 5.9 (2.1 to 16.5)
aBAL, Bronchoalveolar lavage; CI, Confidence interval; DOR, Diagnostic odds
ratio; IPA, Invasive pulmonary aspergillosis; LFD, Aspergillus-specific lateral-flow
device test; NPV, Negative predictive value; PPV, Positive predictive value.
According to European Organization for Research and Treatment of Cancer/
Mycoses Study Group criteria [34], probable IPA cases require mycological
evidence by positive Aspergillus spp BAL culture, cytology, microscopy or positive
galactomannan tests, in addition to host factors and clinical criteria.
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six BAL fluid samples from four patients who did not ful-
fill IPA criteria, but these samples showed growth of vari-
ous Aspergillus species in culture. In addition, the LFD
test results were positive in 3 (14%) of 21 BAL fluid sam-
ples (from 3 patients) with possible IPA. False-negative
LFD results were observed in 4 (20%) of 20 BALs (from 4
patients) with probable or proven IPA (3 of 16 BALs from
patients with probable IPA and 1 of 4 with proven IPA).
In the patient with proven IPA, three consecutive BAL
samples were obtained within 1 month. Whereas the LFD
test results were positive in the first two BAL samples, the
result was negative in the third (under systemic antimold
treatment) while the culture remained positive. In one of
the three patients with probable IPA and false-negative re-
sults, mycological evidence was provided by positive BAL
GM (ODI = 0.72); in the two remaining cases, evidence
was provided by positive BAL culture. (GM testing was
not performed in these latter two cases).
A comparison of the performance of the LFD test with
conventional culture (which was performed in all cases)
for probable or proven IPA versus no IPA according to
modified EORTC/MSG criteria is shown in Table 3. In
addition, BAL GM testing was performed in 53 of 149
BALs, for which the results were positive (ODI > 0.5) in
12 (23%) of the samples. BAL GM results were positive
in 9 of 10 patients with probable or proven IPA and in
3 (7%) of 43 samples from patients without IPA.
Discussion
We performed a multicenter study to evaluate the
Aspergillus LFD test for early IPA diagnosis using BAL
samples in a mixed cohort of ICU patients. The results
across the four participating hospitals show that the LFDtest provides accurate and rapidly available results for
disease detection, with sensitivities and specificities of
about 80% that were consistent when we used three dif-
ferent classification criteria for IPA. The advantages of
the LFD test, which include rapid turnaround time (re-
sults available within 15 minutes) without the need for
specialized laboratory equipment and highly trained
staff, make it a promising alternative to the GM enzyme
immunoassay, which is often not readily available im-
mediately and can therefore delay early initiation of
antifungal therapy.
Invasive fungal infections are an increasing threat in ICU
patients. In Europe, reported incidence rates of IPA among
ICU patients vary widely (0.2% to 6.9%) [9,11,37,38]. When
analyzing only the proportion of patients with routine
bronchoscopy and mycological workup that were
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lence of probable or proven IPA was 11%. The higher rate
may be explained by the fact that only high-risk patients
(with routine mycological workup ordered by the treating
physicians) were included in this study [39].
Previously published studies have shown the high
diagnostic potential of the LFD test for IPA using hu-
man BAL fluid and serum samples in non-ICU patients
[23,24,26,27,30,40]. In patients with SOT, LFD tests of
BAL specimens showed promising diagnostic perform-
ance, with a sensitivity of 91% and a specificity of 83%
[28]. Thus, the performance of the LFD in patients with
SOT was comparable to the current gold standard of IPA
diagnosis (GM testing), which has a sensitivity of 93% and
a specificity of 89% in patients with SOT [41]. Similar
diagnostic accuracy of the LFD was reported in a mixed
population of immunocompromised patients, where sensi-
tivity reached 80% and specificity was 95% [29]. In particu-
lar, the combination of a positive LFD and/or GM test for
IPA diagnosis was very promising (sensitivity 90%, specifi-
city 93%) [29]. Evaluation of the LFD test in patients with
underlying pulmonary diseases yielded a sensitivity of 77%
and specificity of 90% [30].
Two of the previous studies on the LFD test included
ICU patients [29,30]. One study included 104 ICU
patients with underlying pulmonary diseases [30], and
the other include 9 ICU patients, 5 with underlying he-
matologic malignancies and 4 of whom had sepsis. Sum-
marizing the results in the ICU patients of those two
studies (13 patients with probable or proven IPA), the
LFD test had a sensitivity of 77%, a specificity of 90%
and a DOR of 28.5 (95% CI, 6.6 to 123.2). The overall per-
formance of the LFD in ICU patients throughout different
studies highlights the great potential of this point-of-care
test (sensitivity of 79%, specificity of 85% and NPV of 96%).
In particular, the remarkably high 96% or greater NPV of
the LFD test in ICU patients may make it a helpful tool
to prevent overtreatment, which has become frequent in
the ICU setting, as reported by Azoulay and colleagues
[42]. Similarly high NPVs have also been reported in other
studies of the LFD test in other patient groups [27-29].
Sensitivities (75% to 100%) and specificities (78% to
95%) were found to be relatively consistent over all four
participating hospitals, with the exception of Vienna,
where specificity was markedly lower (54%). The fact
that the test’s performance was less convincing in Vienna
than in the other centers might be explained by the differ-
ing inclusion criteria: In Vienna, only samples that grew
molds were included, and most of those originated from
patients without evidence of IPA. In addition, a significant
proportion of samples included in Innsbruck were bio-
bank samples from patients with mostly probable IPA.
Different inclusion criteria, together with small sample
sizes (in particular of probable or proven IPA cases) mayexplain differing PPVs, NPVs and DORs across the four
study sites. Not surprisingly, PPVs were lower and NPVs
higher in those settings (Graz and Mannheim) where ICU
patients undergoing bronchoscopy with mycological
workup were included prospectively than in Vienna and
Innsbruck, where additional biobank samples and/or pre-
selected samples with mold growth were included. PPVs
and NPVs calculated for Graz and Mannheim may there-
fore be more applicable to a real-life medical ICU settings
than those in Innsbruck and Vienna may. Nevertheless,
we want to emphasize the value of adding Innsbruck bio-
bank samples and mold culture–positive samples from
Vienna for validation of sensitivity of this new test for this
rare disease.
False-positive results occurred in 20 patients without
IPA according to slightly modified EORTC/MSG criteria.
As the EORTC/MSG criteria are focused on patients with
hematologic malignancies and are not entirely appropriate
for ICU patients without hematologic diseases, they may
lead to an underestimation of IPA occurrence in these pa-
tients. Therefore, it is conceivable that a proportion of
these false-positive cases might in fact have resulted from
early stages of IPA at the times the bronchoscopies were
performed.
Bergeron and colleagues previously reported that, in
patients with hematologic malignancies, a mycological
diagnostic strategy should be based on underlying disease
and the leukocyte count [13]. Whereas patients with
neutropenia usually develop angioinvasive forms of IPA,
non-neutropenic patients tend to develop airway-invasive
forms. As a consequence, serum biomarkers tend to give a
false-negative result in critically ill non-neutropenic pa-
tients, and diagnostic BAL should be performed in sus-
pected cases of IPA. This is in accordance with data
previously published by Meersseman and colleagues, who
reported a sensitivity of 88% for positive BAL culture
for GM in ICU patients, but a sensitivity of 42% for
serum GM in the same patient cohort [3]. Thus, bron-
choscopy and BAL in non-neutropenic patients with
suspected IPA seems to be crucial, and, in settings where
GM results are not rapidly available, the LFD tests on
BAL specimens might be a very promising alternative
because in eight of nine of our cases with true-
positive BAL GM results, the LFD test also yielded a
positive result.
Consistent with our previously published data, we
show in the present study that the performance of cul-
ture is limited by low sensitivity [10]. In the present
study, the sensitivity of mycological culture reached 50%.
However, in view of the increasing resistance of Aspergil-
lus strains to antifungal drugs [43], mycological culture
is essential for susceptibility testing and may allow de-
tection of other molds (for example, the Mucorales) that
are not detectable by GM or LFD.
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for modifications of the EORTC/MSG revised definitions
of 2008 with the inclusion of ICU stay above 4 days as a
host factor. Modifications were necessary because host
factors in these definitions were originally developed for
severely immunocompromised patients, but they have
not been evaluated in other non-neutropenic patients at
risk for IPA, as described in the Methods section. Al-
though we assume that our modified criteria might be
more appropriate for the ICU population, and even
though all patients who met definitions of probable IPA
had ICU stays of 10 days and longer, the introduction of
“ICU stay above 4 days” as a host factor (although based
on previously published data) might be considered arbi-
trary. Therefore, we also calculated LFD test performance
with predefined EORTC/MSG criteria (without ICU stay
as a host factor) [34] and a previously published clinical
algorithm (which is mainly limited by the fact that it
requires positive Aspergillus culture for putative IPA cases,
which has a sensitivity below 50%) [35], and we found
comparable test performance. Another limitation is that
GM antigen detection in BAL fluid, which seems to be the
most promising diagnostic tool for IPA diagnosis in ICU
patients [3], was not performed in every case. The use of
positive culture results alone as a mycological criterion
may have led to misclassification of IPA in some cases,
which may explain the slight variance of LFD sensitivities
among the participating centers. (The sensitivity of LFD
was higher in those with a positive GM than in those
with positive culture but without GM evaluation.) Also,
whereas LFD testing of 87% of included samples was
performed prospectively, testing of biobank samples
from Innsbruck was performed retrospectively. Previous
studies have shown, however, that BAL LFD test results
may be valid when tested with previously frozen samples
[27-29,44]. Furthermore, demographic data such as under-
lying diseases, as well as the proportion of proven or prob-
able IPA, varied among the participating centers, which
may limit the assessment of the LFD test’s performance.
Conclusions
The use of the LFD test in BAL fluid specimens repre-
sents a promising diagnostic approach for IPA detection
in ICU patients, with sensitivity and specificity compar-
able to previously published data for ICU BAL GM test-
ing. Thus, the LFD test may be viewed as a credible
alternative diagnostic tool in critically ill patients at risk
for IPA in settings where GM evaluations are not rapidly
available. In such settings, the LFD test may facilitate
initiation of early antifungal therapy in patients with
IPA. Future studies should also be done to evaluate the
performance of the LFD test in bronchial secretion and
sputum samples, which have recently been reported to
be equally useful for IPA diagnosis [45].Key message
 The LFD test performed in BAL specimens may be
a promising alternative to the current gold standard
test (GM antigen detection) in ICU patients.
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